Breaking News

Penn Pharma Signs Multiple Clients

By Gil Roth | November 18, 2013

Exceeds expectations with new containment facility

Penn Pharma has secured multiple contracts with companies in Europe, the U.S., and Japan less than two months after officially opening the doors of its new high potency manufacturing facility.
 
The facility was designed to meet the growing market need for contained manufacturing processes. According to a company statement, "Successfully securing multiple global contracts in such a short space of time has verified Penn’s vision and investment strategy that led to the design and build of this new state-of-the-art facility." Penn announced its plans to build the new facility in 2012 and the first batch of coated tablets were produced in May of this year.
 
Richard Yarwood, Penn Pharma’s chief executive officer, commented, “Our vision is to become the preferred partner for the supply of oral doses containing potent molecules for both investigational and commercial use, and this facility will help us to achieve this."
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.